Androgen receptor splicing variant 7: Beyond being a constitutively active variant

Publication date: Available online 21 August 2019Source: Life SciencesAuthor(s): Chen Shao, Bingbing Yu, Yanan LiuAbstractIn prostate cancer development, the androgen receptor (AR) signaling plays a crucial role during both formation of early prostate lesions and progression to the lethal, incurable castration resistant stage. Accordingly, numerous approaches have been developed to inhibit AR activity including androgen deprivation therapy, application of the AR antagonists as well as the use of taxanes. However, these treatments, although effective initially, resistance inevitably occur for most of the patients within several years and limiting the therapeutic efficacy. Of note, alterations and reactivation of the AR signaling pathway have been demonstrated as the major reasons for the observed resistance. Accumulating evidences have suggested that synthesis of AR splicing variants, in particular, the constitutively active AR-V7, is one of the most important mechanisms that contribute to the abnormal AR signaling. In addition, clinical data also highlight the potential of using AR-V7 as a predictive biomarker and a therapeutic target in metastatic castration resistant prostate cancer (mCRPC). In this review, we summarize the recent findings concerning the specific role of AR-V7 in CRPC progression, drug resistance and its potential value in clinical assessment.Graphical abstract
Source: Life Sciences - Category: Biology Source Type: research

Related Links:

Abstract Prostate cancer (PCa) incidence has been rising in Chinese population. Current PSA-based biopsy has limited positive rate. Our research focused on development of serum markers for the diagnosis of PCa in patients with elevated PSA. miRNAs are found to be aberrantly expressed in many types of cancer. They are readily detectable in plasma and serum. Currently, miRNAs are being evaluated as potential prognostic and diagnostic tools for many types of cancer. We first profiled global serum miRNAs in a pilot set of PCa and benign prostatic hyperplasia (BPH) cases undergoing TRUS-guided prostate biopsy due to el...
Source: Biomed Res - Category: Research Authors: Tags: Biomed Res Int Source Type: research
ConclusionIn the everyday practice target biopsy with Koelis™ achieves a good CDR for all PCa and csPCa, which is significantly improved by subsequent systematic sampling of the prostate. The outstanding outcomes of fusion biopsy are confirmed also in biopsy-naïve patients. Elevated PI-RADS score and positive digital rectal examination are strongly associated with presence of PCa.ResumenObjetivosEvaluar la precisión de las biopsias guiada y sistemática para la detección del cáncer de próstata (CP) y CP clínicamente significativo (CPCS) en la práctica diaria, anali...
Source: Actas Urologicas Espanolas - Category: Urology & Nephrology Source Type: research
Treatments for advanced prostate cancer that suppress testosterone, a hormone (also called an androgen) that drives the malignant cells to grow and spread, are collectively referred to as androgen deprivation therapies, or ADT. These therapies can significantly extend lifespans in men who have the disease, but they also have a range of challenging side effects. In 2004, Dr. Marc Garnick, Gorman Brothers Professor of Medicine at Harvard Medical School and Beth Israel Deaconess Medical Center, and editor in chief of, reported that in some men, an ADT drug called aberelix lengthens the time it tak...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Health Living With Prostate Cancer Men's Health Prostate Health Prostate Knowledge Treatments HPK Source Type: blogs
Condition:   Adenocarcinoma of the Prostate Intervention:   Biological: ORCA-010 Sponsors:   Orca Therapeutics B.V.;   CMX Research Not yet recruiting
Source: - Category: Research Source Type: clinical trials
PROSTATE cancer develops when the cells in the prostate start to grow in an uncontrolled way. Knowing the signs and symptoms will ensure early treatment and survival. A certain sign in your semen is a warning sign.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
Authors: Bonk S, Kluth M, Hube-Magg C, Polonski A, Soekeland G, Makropidi-Fraune G, Möller-Koop C, Witt M, Luebke AM, Hinsch A, Burandt E, Steurer S, Clauditz TS, Schlomm T, Perez D, Graefen M, Heinzer H, Huland H, Izbicki JR, Wilczak W, Minner S, Sauter G, Simon R Abstract To assess the prognostic and diagnostic utility of PSA immunostaining, tissue microarrays containing 17,747 prostate cancers, 3,442 other tumors from 82 different (sub) types and 608 normal tissues were analyzed at two different antibody concentrations (1:100 and 1:800). In normal tissues, PSA expression was limited to prostate epithelial c...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Bayer data at ESMO 2019 highlights innovation in cancer researchNew data for larotrectinib on durability of response in patients with TRK fusion cancer to be presented in a poster discussion on September 28 / Data from Bayer's prostate cancer franchise to be presented, including clinical relevance of drug-drug interactions in men with nmCRPC taking darolutamide and real-world data and pain evalutation data in men with mCRPC treated with radium-223 dichloride / New analyses from the Phase II study REGOBONE evaluating the efficacy and safety of regorafenib in patients with rare locally advanced or metastatic relapsed chondro...
Source: Bayer IR Newsfeed: Events - Category: Pharmaceuticals Source Type: news
Patients with non-Hodgkin's lymphoma who received radiation 30 days or less...Read more on AuntMinnie.comRelated Reading: ASTRO: AI predicts side effects from radiation therapy ASTRO: Is hormone therapy after prostate surgery needed? ASTRO: SABR generates immune response to prostate cancer ASTRO: Cervical cancer deaths rise as women's centers close ASTRO: Whole, partial breast RT yield similar cosmetic results
Source: Headlines - Category: Radiology Source Type: news
Cancers, Vol. 11, Pages 1405: Neuroendocrine Differentiation of Prostate Cancer—An Intriguing Example of Tumor Evolution at Play Cancers doi: 10.3390/cancers11101405 Authors: Patel Chugh Tripathi Our understanding of neuroendocrine prostate cancer (NEPC) has assumed a new perspective in light of the recent advances in research. Although classical NEPC is rarely seen in the clinic, focal neuroendocrine trans-differentiation of prostate adenocarcinoma occurs in about 30% of advanced prostate cancer (PCa) cases, and represents a therapeutic challenge. Even though our knowledge of the mechanisms that media...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Publication date: Available online 19 September 2019Source: European UrologyAuthor(s): Nicolai A. Huebner, Shahrokh F. Shariat
Source: European Urology - Category: Urology & Nephrology Source Type: research
More News: Biology | Cancer | Cancer & Oncology | Prostate Cancer